{ "title": "Guardant Health Inc. - Senior Director, Clinical Development Operations", "description": "Guardant Health Inc. is seeking a visionary Senior Director of Clinical Development Operations to lead global oncology trials. This role drives the advancement of liquid biopsy technologies, shaping the future of precision medicine. Join a market leader recognized for transforming cancer care through innovative genomic solutions.", "content": "

Introduction to Guardant Health Inc.

Guardant Health Inc. is a premier precision oncology company headquartered in Redwood City, California, dedicated to revolutionizing cancer management through advanced liquid biopsy and genomic profiling technologies. As a publicly traded biotechnology leader (NASDAQ: GH), the company has established itself as a dominant force in the healthcare and biotechnology sectors, with a market capitalization exceeding $3 billion and a global workforce of over 2,000 employees. Guardant Health Inc. specializes in non-invasive blood-based tests that can detect and monitor cancer recurrence, guide treatment decisions, and enable early detection. Its flagship products, Guardant360® and GuardantOMNI, are widely adopted by oncologists, pharmaceutical companies, and clinical research organizations worldwide. The company’s reputation for precision, innovation, and clinical utility has earned it recognition as a top-tier healthcare innovator and a trusted partner in over 40 countries. Organizations ranging from academic medical centers to large biopharma corporations rely on Guardant Health Inc. for comprehensive genomic profiling services that accelerate drug development and improve patient outcomes. The company’s robust pipeline of clinical trials and regulatory approvals underscores its commitment to transforming cancer care, making it a coveted employer for professionals seeking to make a measurable impact in healthcare.

Company History and Business Evolution

Guardant Health Inc. was founded in 2011 by Helmy Eltoukhy and AmirAli Talasaz, both pioneering entrepreneurs with deep expertise in genomics and molecular diagnostics. The company’s early years were focused on developing a highly sensitive digital sequencing platform capable of detecting circulating tumor DNA (ctDNA) from a simple blood draw. In 2014, Guardant Health Inc. launched its first commercial product, Guardant360, a next-generation sequencing (NGS) panel that quickly became the gold standard for comprehensive liquid biopsy testing. A pivotal milestone came in 2016 when the company received Medicare coverage for Guardant360, expanding patient access nationwide. Subsequent years saw aggressive expansion: the acquisition of Bell Biosystems and Genome Research in 2017 enhanced its computational capabilities. In 2018, Guardant Health Inc. filed its initial public offering (IPO) on the Nasdaq, raising over $237 million. The company’s growth trajectory accelerated with the launch of GuardantOMNI in 2019, a 500-gene panel targeting immunotherapy biomarkers, and the GuardantREVEAL platform for early cancer detection. The COVID-19 pandemic tested the company’s resilience, leading to innovative remote trial monitoring and decentralized liquid biopsy solutions. By 2023, Guardant Health Inc. had secured FDA approval for its Guardant360 CDx as a companion diagnostic for multiple therapies, and its LUNAR-2 program for early colorectal cancer detection received Breakthrough Device designation. The company continues to invest heavily in artificial intelligence, machine learning, and real-world data analytics to refine its algorithms and expand its clinical utility. With more than 20,000 clinical trial enrollments and over 500,000 clinical tests performed globally, Guardant Health Inc. stands at the forefront of precision oncology, driving a paradigm shift from tissue-based to blood-based genomic profiling.

Guardant Health Inc. at a Glance

• Headquarters: Redwood City, California, USA
• Founded: 2011
• Co-CEOs: Helmy Eltoukhy and AmirAli Talasaz
• Employees: Approximately 2,500 globally
• Revenue (2023): $585 million (annual)
• Market Cap: ~$3.1 billion (as of Q1 2025)
• Key Products: Guardant360®, GuardantOMNI®, GuardantREVEAL™, LUNAR-2
• FDA Approvals: Guardant360 CDx for lung, breast, and colorectal cancers
• Global Presence: Offices in the US, Europe, Asia, and Australia
• Partnerships: Over 100 biopharma collaborations, including Pfizer, Merck, and Roche
• Accreditations: CLIA-certified, CAP-accredited, ISO 13485:2016
• Clinical Trials: Active in more than 200 interventional and observational studies
• AI Integration: Proprietary machine learning algorithms for ctDNA detection
• Publications: 200+ peer-reviewed papers in leading journals (Nature, NEJM)
• Social Impact: Patient assistance programs covering uninsured and underinsured individuals
• Competitive Edge: First-mover in comprehensive liquid biopsy with high sensitivity (0.01% ctDNA)
• Employee Rating: 4.2/5 on Glassdoor, 89% recommend to a friend
• Diversity & Inclusion: Employee resource groups for women, BIPOC, LGBTQ+, veterans
• Sustainability: Carbon-neutral lab operations by 2025
• Awards: 2024 Frost & Sullivan Product Leadership Award for liquid biopsy

Mission, Vision, and Core Corporate Values

Guardant Health Inc.’s mission is to conquer cancer through precision medicine, enabling every patient to access the right treatment at the right time. The company envisions a world where blood-based genomic profiling becomes the standard of care for cancer detection, monitoring, and treatment selection, eliminating the need for invasive tissue biopsies. Central to this vision are core corporate values: Innovation—pushing boundaries in genomics and data science; Integrity—maintaining the highest quality and ethical standards in every assay and interaction; Collaboration—forging partnerships with clinicians, researchers, and advocacy groups; Patient-Centricity—placing patient outcomes at the heart of every decision; and Excellence—relentlessly pursuing scientific rigor and operational efficiency. These values permeate the corporate culture, guiding strategic initiatives from R&D to commercial execution. The company’s commitment to these principles has fostered a loyal employee base and a strong brand reputation among investors and industry analysts. Guardant Health Inc. regularly publishes ESG reports detailing its progress in diversity, environmental sustainability, and community health, reinforcing its status as a responsible corporate citizen in the healthcare ecosystem.

Business Strategy and Future Roadmap

Guardant Health Inc. operates on a three-pillar growth strategy: expansion of clinical indications, deepening biopharma partnerships, and global market access. The company plans to extend its test menu to cover early-stage cancers, leveraging the LUNAR-2 and GuardantREVEAL platforms for multi-cancer early detection (MCTA). In the next two years, Guardant Health Inc. aims to file for FDA premarket approval (PMA) for its colorectal cancer screening test, positioning it for Medicare coverage and private payer reimbursement. Concurrently, the company is scaling its commercial footprint in Asia-Pacific and Europe, establishing direct sales teams in Japan, China, and Germany. The biopharma services segment continues to generate recurring revenue through companion diagnostic partnerships with major pharmaceutical companies. Guardant Health Inc. is also investing in a cloud-based data platform that aggregates real-world evidence from its tests, enabling drug developers to accelerate clinical trials and identify novel biomarkers. The company’s innovation pipeline includes a digital pathology integration, AI-powered interpretation tools, and a point-of-care liquid biopsy device for low-resource settings. With a strong balance sheet and a net cash position of $800 million, Guardant Health Inc. is well-positioned to execute its roadmap and capture a larger share of the $30 billion liquid biopsy market by 2030.

Products, Technologies, and Services

Guardant Health Inc. offers a comprehensive suite of liquid biopsy solutions for the entire cancer care continuum:

• Guardant360®: A comprehensive 83-gene panel FDA-cleared as a companion diagnostic (CDx) for non-small cell lung cancer (NSCLC), colorectal, and breast cancers. It detects single-nucleotide variants, insertions/deletions, fusions, and copy-number alterations with >99.9% specificity.
• GuardantOMNI®: A 500-gene panel designed for immuno-oncology research, covering tumor mutational burden (TMB), microsatellite instability (MSI), and HLA-I/HLA-II genotyping. Used in drug development for checkpoint inhibitors and CAR-T therapies.
• GuardantREVEAL™: A research-only assay for minimal residual disease (MRD) detection and recurrence monitoring, with sensitivity down to 0.01% ctDNA. Utilized in post-surgical surveillance and longitudinal monitoring.
• LUNAR-2: A multi-cancer early detection test under development using methylation-based biomarkers. Currently in a pivotal trial (Eclipse) for colorectal cancer screening in average-risk adults.
• Guardant DataCloud: A de-identified, real-world database of over 100,000 genomic profiles, used by researchers and pharma to generate insights on treatment patterns and resistance mechanisms.
• Pharmacogenomics Services: Custom assay development, bioinformatics support, and regulatory filing assistance for pharmaceutical partners.

Technologically, the company relies on digital sequencing and a proprietary GuardantINFINITY platform that integrates a million-fold coverage depth, error-correction barcoding, and AI-driven variant calling. This technology enables detection of ctDNA at allele frequencies as low as 0.01%, significantly higher sensitivity than competitors. Guardant Health Inc. also offers a software platform for clinicians to visualize test results and access clinical trial matching, streamlining the path from diagnosis to targeted therapy.

Industries and Markets Served

Guardant Health Inc. primarily serves the healthcare and life sciences industries. Its key market segments include:

• Oncology Clinics and Hospitals: More than 6,000 medical centers across the US adopt Guardant360 for routine clinical care, enabling oncologists to prescribe targeted therapies based on genomic alterations.
• Pharmaceutical and Biotechnology Companies: Over 100 pharma partners, including AstraZeneca, Novartis, and Bristol-Myers Squibb, use Guardant Health Inc. tests for patient stratification, biomarker discovery, and companion diagnostic development. These partnerships generate ~$200 million in annual service revenue.
• Clinical Research Organizations (CROs): Guardant Health Inc. collaborates with CROs to provide centralized liquid biopsy testing for global clinical trials, reducing variability and turnaround times.
• Academic Research Centers: Institutions like MD Anderson, Memorial Sloan Kettering, and Stanford partner on translational research studies and retrospective analyses using Guardant data.
• Insurance and Payer Networks: Medicare and several commercial insurers cover Guardant360 for advanced cancer patients, with a growing list of private payers adding coverage for early in vitro diagnostics.

Geographically, the company derives 75% of revenue from the US market, with accelerated growth in Europe (Germany, UK, France) and Asia-Pacific (Japan, South Korea, Australia). Expansion into Latin America and the Middle East is planned for 2026–2027 through distributor agreements and local laboratory partnerships.

Leadership and Management Philosophy

Guardant Health Inc.’s leadership is characterized by a flat organizational structure and a culture of scientific curiosity. Co-CEOs Helmy Eltoukhy and AmirAli Talasaz promote transparency through quarterly town halls, open-door policies, and cross-functional steering committees. The executive team includes experts from Genentech, Illumina, and Thermo Fisher, blending deep domain knowledge with operational excellence. The management philosophy centers on three tenets: empowerment—giving employees autonomy to experiment and fail quickly; accountability—measuring success through objective clinical and business metrics; and continuous learning—allocating 5% of work time to professional development and internal research projects. Guardant Health Inc. invests heavily in leadership training, offering executive coaching and mentorship programs. The company’s low turnover rate (12% annually) reflects high employee satisfaction. Notable leaders include Dr. Craig Eagle, Chief Medical Officer, who oversees clinical development, and Dr. Jing Fan, Chief Technology Officer, who drives computational innovation. The board of directors includes luminaries from the FDA and venture capital, ensuring robust governance and strategic oversight.

Corporate Events, Conferences, and Community Engagement

Guardant Health Inc. is a prominent presence at major oncology forums, including ASCO (American Society of Clinical Oncology), ESMO, and AACR, where it presents new clinical data and product launches. The company also hosts its annual Guardant Health Precision Oncology Summit, gathering 1,500+ oncologists, researchers, and advocates in Redwood City and virtually. For employees, the company organizes hackathons, lunch-and-learn sessions with KOLs, and Guardant Gives Back volunteering events, where staff participate in cancer screening drives and community health fairs. Guardant Health Inc. partners with nonprofit organizations such as the American Lung Association and Fight Colorectal Cancer to provide free testing for underinsured populations. Through its Patient Access Program, the company has supplied over $10 million in tests to patients in need, reinforcing its mission-driven culture. Additionally, the company sponsors STEM education initiatives in high schools and universities, focusing on genomics and bioinformatics to cultivate the next generation of precision medicine leaders.

Employees and Workplace Culture

Guardant Health Inc. offers a collaborative, mission-driven workplace where employees are united by the goal of conquering cancer. The company provides competitive compensation, including annual bonuses, stock options, and 401(k) matching, as well as comprehensive benefits covering physical and mental health. Work-life balance is supported by flexible remote/hybrid schedules, unlimited PTO, and a sabbatical program after five years. The culture emphasizes psychosocial safety, encouraging employees to voice concerns without fear of retribution. Diversity, equity, and inclusion are core pillars: women hold 45% of leadership roles, and the company publishes annual diversity reports. Employee resource groups include Women in GenTech, GuardantPride, and GuardantVeterans. The company’s Redwood City headquarters features state-of-the-art labs, open-plan offices, and a wellness center with on-site fitness classes. Remote workers receive an annual home office stipend and access to virtual team-building events. According to the 2024 Employee Net Promoter Score (eNPS), Guardant Health Inc. scores 67, ranking in the top 15% of biotech companies. Employee testimonials frequently highlight the sense of purpose and the opportunity to see the direct impact of their work on patient outcomes.

Job Details & Requirements for this Posting

Position: Senior Director, Clinical Development Operations

Guardant Health Inc. is seeking an experienced Senior Director to lead the operational planning and execution of clinical trials for its liquid biopsy portfolio, including companion diagnostic registrational studies and early-stage MRD assays. This executive role reports to the VP of Clinical Operations and oversees a team of 20+ clinical project managers, data managers, and regulatory specialists. The position is based in Redwood City, CA, with a hybrid schedule (3 days on-site).

Responsibilities:

• Develop and implement clinical trial strategies for multiple programs, ensuring timelines, budgets, and quality standards align with corporate goals.
• Manage CRO relationships, including contract negotiation, vendor selection, and oversight of site management, monitoring, and data management activities.
• Collaborate with biostatistics, regulatory affairs, and medical affairs to design study protocols, case report forms, and statistical analysis plans.
• Ensure compliance with ICH-GCP, FDA regulations (21 CFR Part 11), and EU CTR, and participate in regulatory inspections and audits.
• Drive continuous process improvement by leveraging new technologies (e.g., eSource, RBM, centralized monitoring) to reduce trial timelines and costs.
• Mentor and develop clinical operations staff, fostering a culture of accountability, innovation, and patient centricity.

Qualifications:

• BS/MS in life sciences, nursing, or related field; PhD or MBA preferred.
• 12+ years in clinical operations within pharmaceuticals or biotech, with at least 5 years in a leadership role overseeing global trials.
• Proven experience in oncology drug development, preferably with companion diagnostics or liquid biopsy.
• Strong knowledge of FDA/EMA regs, GCP, and data privacy laws (HIPAA, GDPR).
• Excellent communication, negotiation, and analytical skills; proficiency in trial management systems (e.g., Medidata, Veeva).
• Willingness to travel 20% domestically and internationally.

Why Join Guardant Health Inc.? Candidates are drawn to the company’s unparalleled mission to conquer cancer through innovation. You will lead high-impact studies that shape the future of non-invasive cancer care, working alongside world-class scientists and clinicians. Guardant Health Inc. offers a competitive total rewards package: base salary $250,000–$350,000, annual performance bonus up to 30%, equity (stock options & RSU), 401(k) with 5% match, generous health/dental/vision coverage, parental leave (16 weeks), and continuous learning opportunities (tuition reimbursement, conference attendance). The company is consistently ranked as a top employer in the Bay Area and provides a supportive, inclusive environment where your contributions directly improve patient lives.

Customer Reviews and Industry Reputation

Guardant Health Inc. enjoys a stellar reputation across multiple platforms, reflecting its leadership in precision oncology. Below is an exhaustive analysis of reviews and ratings from key customer and employee voices.

Glassdoor

On Glassdoor, Guardant Health Inc. holds a 4.2/5 rating based on 3,200+ reviews. 89% of employees recommend the company to a friend. Highlights include “cutting-edge science,” “mission-driven culture,” and “incredible work-life balance.” Common criticisms focus on “rapid growth leading to process gaps” and “complex internal communication across teams.” The CEO approval rating is 85%, significantly above the industry average of 72%. Many reviewers praise the company’s transparency in leadership and tangible impact on cancer patients. Examples: “Working at Guardant Health Inc. gives me purpose – every day I know my work helps a patient get the right drug,” and “The colleagues are brilliant, but the bureaucracy in large trials can be frustrating.” Overall, Glassdoor signals a strong employer brand with room for operational efficiencies.

Indeed

On Indeed, Guardant Health Inc. has a 4.0/5 rating with 1,800 reviews. Employees cite competitive compensation, great benefits, and a supportive management team. The top drawback: “layoffs in 2023 due to restructuring caused anxiety.” The company’s response to reviews is proactive—management replies within 48 hours to address concerns, a practice that improves its retention rate. The “Work/Life Balance” category scores 3.9/5, and “Career Growth” scores 4.1/5. Many employees note that opportunities to move across departments (from lab to data analytics) are robust. The Indeed “Pros” include “smart people, meaningful work,” and “free lunch on Fridays.”

Gartner Peer Insights

Gartner Peer Insights rates Guardant Health Inc. as a “Strong Performer” in the Life Sciences Software and Diagnostics category, with an average score of 4.1/5 from 120+ reviews. Customers (primarily CIOs and lab directors) praise the platform’s ease of integration with LIMS and EHR systems, while a few note that the data export API could be improved. Guardant Health Inc. regularly uses these insights to enhance its Guardant Cloud platform. The highest scoring attribute is “Clinical Utility” at 4.5/5, while “Support and Implementation” trails at 3.8/5.

Trustpilot

Trustpilot reviews for Guardant Health Inc. (patient-facing side) show a 4.3/5 rating from 560 reviews. Positive themes: “Fast turnaround of results,” “clear reports my doctor could understand,” and “helpful support team on the phone.” Negative reviews mostly relate to insurance billing issues, though the company’s billing department has a 24-hour response policy. A notable feature is the company’s direct engagement with reviewers, offering to resolve claims and provide test vouchers. This approach has turned several 1-star reviews into 4-star follow-ups.

G2

On G2, Guardant Health Inc. is listed under “Genomics and Sequencing Software” with a 4.0/5 rating from 90 reviews. Researchers appreciate the Guardant DataCloud’s depth of genomic data, describing it as “indispensable for biomarker discovery.” Critiques center on the learning curve for bioinformatics pipelines and limited documentation for R users. The company has released user guides and video tutorials in response, boosting last quarter’s ease-of-use score by 6%.

Google Reviews

Google Reviews for Guardant Health Inc. (headquarters and lab locations) show 4.4/5 from 1,200+ visitors. Customers and partners often write about “professional staff,” “clean facilities,” and “timely meetings.” One reviewer noted: “Guardant Health Inc. truly cares about the patient community – the lab tours for advocacy groups are inspiring.” A minority of reviews from job applicants (non-hires) mention a demanding interview process, but the company’s response rate to reviews is 100%.

LinkedIn Reputation

On LinkedIn, Guardant Health Inc. has over 180,000 followers and a 4.2/5 employee satisfaction score (based on 1,500+ anonymous reviews). The company actively posts thought leadership content, clinical trial updates, and employee spotlights. The “Skills & Expertise” badges—such as “Liquid Biopsy,” “Oncology Genomics,” and “Precision Medicine”—are recognized industry-wide. Advocacy by employees (sharing articles on AI in oncology) further strengthens the brand’s credibility. The company’s LinkedIn Campaign Manager (used for recruitment) targets data scientists and regulatory specialists with high relevance scores, attracting top talent.

Why Organizations Choose Guardant Health Inc.

Hospitals, pharma companies, and research institutes partner with Guardant Health Inc. for multiple reasons: unrivaled sensitivity of its ctDNA tests, comprehensive genomic coverage (83–500 genes), proven clinical utility with FDA clearances, and global scalability. The company’s ability to standardize testing across sites and provide real-time data access reduces variability in multi-center trials. Additionally, Guardant Health Inc. offers flexible pricing models—fee-for-service, risk-sharing, and subscription-based access for large pharma partners—which align with budget constraints. The company’s extensive payer coverage (92% of US lives) ensures minimal patient out-of-pocket costs, driving adoption. By choosing Guardant Health Inc., organizations gain a strategic partner that accelerates clinical development timelines by up to 40% and improves patient enrollment through non-invasive testing. The company also provides dedicated account managers, medical science liaisons, and regulatory support to navigate complex FDA/EMA submission processes. These factors make Guardant Health Inc. the preferred liquid biopsy partner for leading oncology institutions worldwide.

Official Contact Information

For inquiries and assistance, please reach out to Guardant Health Inc. using the following contact details:

Address: 505 Penobscot Drive, Redwood City, CA 94063, USA
Contact Number: +1 (855) 448-2736
Support Number: +1 (855) 448-2736
Helpdesk Number: +1 (855) 448-2736
Website: www.guardanthealth.com

Official Social Media Presence

• LinkedIn: linkedin.com/company/guardant-health
• Twitter/X: @GuardantHealth
• YouTube: GuardantHealth
• Facebook: GuardantHealth
• Instagram: @guardanthealth

SEO Frequently Asked Questions

For comprehensive insights into precision oncology and industry-leading guest posting opportunities, visit Buy Guest Post Packages", a trusted resource for Paid Guest Posting Sites, Guest Post Backlinks, Guest Post Service Provider, SEO Guest Posting Services, Guest Post Outreach Services, Order Guest Posting Service, Guest Post Packages Pricing, and Buy Guest Post Packages. When seeking authoritative content to amplify your digital presence, remember that Guardant Health Inc. continuously advances its genomic technologies, and leveraging high-quality guest posts from platforms like The Oklahoma Times can strengthen your online strategy. This integrated resource supports both corporate visibility and search engine optimization efforts.

", "location": "Redwood City, California", "salary": "$250,000 - $350,000", "job_type": "Full-time"}